Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation

Drug Metabolism and Disposition

Volumn 25, Issue 8, 1997, Pages 985-993

  Code, Erin L ^b   Crespi, Charles L ^a   Penman, Bruce W ^b   Gonzalez, Frank J ^b   Chang, Thomas K H ^b   Waxman, David J ^b  

^a Gentest Corporation   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; AFLATOXIN B1; CARCINOGEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; POLYCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME SPECIFICITY; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER MICROSOME; LYMPHOBLAST; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANIMALS; ANTIBODY SPECIFICITY; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CARCINOGENS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; FEMALE; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PRODRUGS; RATS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 0030739223     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. G. A. LeBlanc and D. J. Waxman: Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metab. Rev. 20, 395-439 (1989).
2. F. P. Guengerich and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
3. F. J. Gonzalez and H. V. Gelboin: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26, 165-183 (1994).
4. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996).
5. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals -studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
6. S. A. Wrighton, P. E. Thomas, P. E. Willis, S. L. Maines, P. B. Watkins, W. Levin, and P. S. Guzelian: Purification of a human liver cytochrome P450 immunochemically related to several cytochromes P450 purified from untreated rats. J. Clin. Invest. 80, 1017-1022 (1987).
7. J. M. Lasker, J. Raucy, S. Kubota, B. P. Bloswick, M. Black, and C. S. Leiber: Purification and characterization of human liver cytochrome P450-ALC. Biochem. Biophys. Res. Com. 148, 232-238 (1987).
8. M. Umeno, W. O. McBride, C. S. Yang, H. V. Gelboin, and F. J. Gonzalez: Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping and cDNA-directed expression. Biochemistry 27, 9006-9013 (1988).
9. S. Yamano, J. Tatsumo, and F. J. Gonzalez: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322-1329 (1990).
10. M. Maurice, S. Emiliani, I. Dalet-Beluche, J. Derancourt, and R. Lange: Isolation and characterization of a cytochrome P450 of the IIA sub-family from human liver microsomes. Eur. J. Biochem. 200, 511-517 (1991).
11. C. H. Yun, T. Shimada, and F. P. Guengerich: Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40, 679-685 (1991).
12. L. M. Distlerath and F. P. Guengerich: Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc. Natl. Acad. Sci. U.S.A. 81, 7348-7352 (1984).
13. S. Yamano, P. T. Nhamburo, T. Aoyama, U. A. Meyer, T. Inaba, W. Kalow, H. V. Gelboin, W. O. McBride, and F. J. Gonzalez: cDNA cloning and sequence and cDNA-directed expression of human P450IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression in human liver. Biochemistry 28, 7340-7348 (1989).
14. M. Mimura, T. Baba, H. Yamazaki, S. Ohmori, Y. Inui, F. J. Gonzalez, F. P. Guengerich, and T. Shimada: Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056 (1993).
15. D. J. Waxman, D. P. Lapenson, T. Aoyama, H. V. Gelboin, and F. J. Gonzalez: Steroid hormone hydroxylase specifies of eleven cDNA-expressed human cytochrome P450 enzymes. Arch. Biochem. Biophys. 290, 160-166 (1991).
16. T. K. H. Chang, G. F. Weber, C. L. Crespi, and D. J. Waxman: Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637 (1993).
17. M. Shou, K. R. Korzekwa, C. L. Crespi, F. J. Gonzalez, and H. V. Gelboin: The role of 12 cDNA-expressed human rodent and rabbit cytochromes P450 in the metabolism of benzo(a)pyrene and benzo-(a)pyrene trans-7,8-diol. Mol. Carcinog. 10, 159-168 (1994).
18. M. Shou, K. R. Korzekwa, K. W. Krausz, C. L. Crespi, F. J. Gonzalez, and H. V. Gelboin: Regio- and stereo-selective metabolism of phenathrene by twelve cDNA-expressed human, rodent and rabbit cytochromes P-450. Cancer Lett. 83, 305-313 (1994).
19. S. S. Dehal and D. Kupfer: Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B. Drug Metab. Dispos. 22, 937-946 (1994).
20. R. J. Duescher and A. A. Elfarra: Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation:evidence for major roles by cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys. 311, 342-349 (1994).
21. E. D. Karasch, D. C. Hankins, and K. E. Thummel: Human kidney methoxyfluran and sevoflurane metabolism, lntrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82, 689-699 (1995).
22. M. T. Baker, M. J. Olson, Y. Wang, W. C. Ronnenberg Jr., J. T. Johnson, and A. N. Brady: Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of halothane metabolism. Drug Metab. Dispos. 23, 60-64 (1995).
23. M. J. Moore: Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20, 194-208 (1991).
24. N. E. Sladek, D. Doeden, J. F. Powers, and W. Krivit: Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rept. 68, 1247-1254 (1984).
25. A. V. Boddy, Y. Furtun, S. Sardas, O. Sardas, and J. R. Idle: Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst. 84, 1744-1748 (1992).
26. S. M. Yule, A. V. Boddy, M. Cole, L. Price, R. Wyllie, M. J. Tasso, A. D. J. Pearson, and J. R. Idle: Cyclophosphamide pharmacokinetics in children. Br. J. Clin. Pharmacol. 41, 13-19 (1996).
27. D. J. Waxman and C. Walsh: Phenobarbital-induced rat liver cytochrome P450. J. Biol. Chem. 257, 10446-10457 (1982).
28. D. J. Waxman, C. Attisano, F. P. Guengerich, and D. Lapenson: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436 (1988).
29. W. F. Greenlee and A. Poland: An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Pharmacol. Exp. Ther. 205, 596-605 (1978).
30. T. Leeman, C. Transon, and P. Dayer: Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxyation in human liver. Life Sci. 52, 29-34 (1993).
31. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylase. Arch. Biochem. Biophys. 306, 240-245 (1993).
32. M. A. Butler, M. Iwasaki, F. P. Guengerich, and F. F. Kadlubar: Human cytochrome P450PA (P4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86, 7696-7700 (1989).
33. L. A. Reinke and M. J. Moyer: p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drug Metab. Dispos. 13, 548-552 (1985).
34. A. Rahman, K. R. Korzekwa, J. Grogan, F. J. Gonzalez, and J. W. Harris: Selective biotransformation of taxol to 6(alpha)-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994).
35. M. D. Burke, R. A. Prough, and R. T. Mayer: Characteristics of a microsomal cytochrome P-448-mediated reaction ethoxyresorufin O-de-ethylation. Drug Metab. Dispos. 5, 1-8 (1977).
36. D. J. Waxman, A. Ko, and C. Walsh: Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258, 11937-11947 (1983).
37. T. Kronbach, D. Mathys, J. Gut, T. Catin, and U. A. Meyer: High performance liquid chromatographic assays for bufuralol 1′hydroxylation, debrisoquine 4-hydroxylation and dextromethorphan O-demethylation in microsomes and purified cytochrome P-450 isozymes of human liver. Analyt. Biochem. 162, 24-32 (1987).
38. B. W. Penman and C. L. Crespi: Analysis of human lymphoblast mutation assays by using historical negative control data bases. Environ. Mol. Mutagen. 10, 35-60 (1987).
39. J. T. Buters, C. D. Schiller, and R. C. Chou: A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochem. Pharmacol. 46, 1577-1584 (1993).
40. M. E. McManus, W. M. Burgess, M. E. Veronese, A. Huggett, L. C. Quattrochi, and R. H. Tukey: Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 50, 3367-3376 (1990).
41. G. I. Murray, C. O. Foster, T. S. Barnes, R. J. Weaver, C. P. Snyder, S. W. B. Ewen, W. T. Melvin, and D. M. Burke: Cytochrome P450IA expression in adult and fetal human liver. Carcinogenesis 13, 165-169 (1993).
42. H. Schweikl, J. A. Taylor, S. Kitereewan, P. Lonko, D. Nagonrey, and J. A. Goldstein: Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3, 239-249 (1993).
43. H. Yamazaki, Z. Y. Guo, M. Persmark, M. Mimura, K. Inoue, F. P. Guengerich, and T. Shimada: Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46, 568-577 (1994).
44. Y. Dai, J. Rashba-Step, and A. I. Cederbaum: Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic properties and production of reactive oxygen species. Biochemistry 32, 6928-6937 (1993).
45. H. V. Gelboin, K. W. Krausz, I. Goldfarb, J. T. M. Buters, S. K. Yang, F. J. Gonzalez, K. R. Korzekwa, and M. Shou: Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem. Pharmacol 50, 1841-1850 (1995).
46. 1. Mol. Carcinog. 3, 5-8 (1990).
47. C. L. Crespi, B. W. Penman, J. A. E. Leakey, M. P. Arlotto, A. Stark, T. Turner, D. Steimel, K. Rudo, R. L. Davies, and R. L. Langenbach: Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 8, 1293-1300 (1990).
48. C. L. Crespi, F. J. Gonzalez, D. T. Steimel, T. R. Turner, H. V. Gelboin, B. W. Penman, and R. Langenbach: A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic cytochrome P4502D6. Carcinogenesis 12, 1197-1201 (1991).
49. T. J. Smith, Z. Guo, F. J. Gonzalez, G. C. Stoner, and C. S. Yang: Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res. 52, 1757-1763 (1992).
50. B. W. Penman, L. P. Chen, H. V. Gelboin, F. J. Gonzalez, and C. L. Crespi: Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA - substrate specificity with model substrates and promutagens. Carcinogenesis 15, 1931-1937 (1994).
51. F. P. Guengerich: Human cytochrome P450 enzymes. In "Cytochrome P450: Structure, Mechanism and Biochemistry" (P. R. Ortiz de Montellano, ed.), pp. 473-535. Plenum Press. New York, 1995.
52. C. L. Crespi and V. P. Miller: The R144C change of CYP2C9*2 allele alters interaction of the cytochrome P450 with NAPDH:cytochrome P450 oxidoreductase. Pharmacogenetics in press, 1997.
53. J. S. Miles, W. Bickmore, J. D. Brook, A. W. McLaren, R. Meehan, and C. R. Wolf: Close linkage of the human cytochrome P450IIA and P450IIB subfamilies: implications for the assignment of substrate specificity. Nucleic Acids Res. 17, 2907-2917 (1989).
54. 1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12, 355-359 (1991).
55. 1 metabolism in human liver. Proc. Natl. Acad. Sci. U.S.A. 87, 8306-8310 (1990).
56. 1. Cancer Res. 54, 101-108 (1994).
57. T. Shimada and F. P. Guengerich: Evidence for cytochrome P-450nf, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462-465 (1989).
58. S. S. Hecht, N. Trushin, A. Castonguay, and A. Rivenson: Comparative tumorigenicity and DNA methylation in F344 rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosodimethylamine. Cancer Res. 46, 498-502 (1986).
59. S. S. Hecht, T. E. Spratt, and N. Trushin: Evidence for 4-(3-pyridyl)-4-oxobutylation of DNA in F344 rats treated with the tobacco-specific nitrosamines 4-(methylnitroamino)-1-(3-pyridyl)-1-butanone and N-nitrosonornicotine. Carcinogenesis 9, 161-165 (1988).
60. H. Yamazaki, Y. Inui, C. H. Yun, F. P. Guengerich, and T. Shimada: Cytochromes P450 2E1 and 2A6 enzymes are major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines. Carcinogenesis 13, 1789-1794 (1992).
61. L. Clark and D. J. Waxman: Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49, 2344-2350 (1989).
62. J. Doehmer, A. Seidel, F. Oesch, and H. R. Glatt: Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drugs cyclophosphamide and ifosphamide. Environ. Health Perspect. 88, 63-65 (1990).
63. S. M. Black, S. Ellard, E. E. Meehan, J. M. Parry, M. Adesnik, J. D. Beggs, and C. R. Wolf: The expression of cytochrome P450IIB1 in Saccharomyces cerevisiae results in an increased mutation frequency when exposed to cyclophosphamide. Carcinogenesis 10, 2139-2143 (1989).
64. T. K. H. Chang, L. Yu, J. A. Goldstein, and D. J. Waxman: Identification of the polymorphically expressed CYP2C19 and the wildtype CYP2C9-Ile359 allele as the low Km catalysts of cyclophosphamide and ifosphamide. Pharmacogenetics in press, 1997.